{"id":567599,"date":"2026-10-27T14:04:13","date_gmt":"2026-10-27T14:04:13","guid":{"rendered":"https:\/\/www.europesays.com\/pt\/567599\/"},"modified":"2026-10-27T14:04:13","modified_gmt":"2026-10-27T14:04:13","slug":"anvisa-autoriza-testes-em-humanos-de-vacina-brasileira-contra-malaria-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/pt\/567599\/","title":{"rendered":"Anvisa autoriza testes em humanos de vacina brasileira contra mal\u00e1ria"},"content":{"rendered":"<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Trata-se da <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">Vivaxin<\/strong>, imunizante que pretende combater a infec\u00e7\u00e3o causada pelo parasita plasmodium vivax, um dos <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">principais causadores da mal\u00e1ria<\/strong> no Brasil.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Os <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">ensaios cl\u00ednicos<\/strong> ser\u00e3o realizados em 48 volunt\u00e1rios saud\u00e1veis, de 18 a 59 anos, em Minas Gerais. A vacina foi desenvolvida pelo <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">CTVacinas da UFMG<\/strong> (Universidade Federal de Minas Gerais), em parceria com a USP (Universidade de S\u00e3o Paulo) e o laborat\u00f3rio Crist\u00e1lia.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Atualmente, a OMS (Organiza\u00e7\u00e3o Mundial da Sa\u00fade) recomenda dois imunizantes contra a doen\u00e7a, s\u00e3o eles: a <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">RTS,S\/AS01 e a R21\/Matrix-M,<\/strong> que protegem contra outra esp\u00e9cie do parasita, o P. falciparum.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Se aprovado depois das pr\u00f3ximas fases,<strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\"> Vivax revolucionar\u00e1 o mercado como o primeiro imunizante<\/strong> a combater o P.Vivax. <\/p>\n<p>In\u00edcio dos testes cl\u00ednicos<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">O protocolo prev\u00ea<strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\" style=\"font-size: 16px;\"> 48 volunt\u00e1rios saud\u00e1veis<\/strong>, de 18 a 59 anos, que nunca tiveram mal\u00e1ria.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Ser\u00e3o testadas tr\u00eas dosagens, e os participantes receber\u00e3o a Vivaxin ou um placebo. Cada pessoa tomar\u00e1 tr\u00eas doses, com intervalo de 28 dias entre elas.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">O acompanhamento durar\u00e1 360 dias, com avalia\u00e7\u00f5es cl\u00ednicas e monitoramento. O estudo ser\u00e1 realizado no Centro de Pesquisas Cl\u00ednicas do Hospital das Cl\u00ednicas da UFMG, em Belo Horizonte.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Essa \u00e9 a chamada fase 1, a primeira etapa de testes em humanos. Os objetivos s\u00e3o avaliar:<\/p>\n<ul class=\"list-none [li&gt;&amp;]:pl-5\" style=\"text-align: justify;\">\n<li class=\"[ul&gt;&amp;]:indent-5 mb-3 break-words [ul&gt;&amp;]:relative [ul&gt;&amp;]:before:absolute [ul&gt;&amp;]:before:left-1 [ul&gt;&amp;]:before:top-2 [ul&gt;&amp;]:before:w-2 [ul&gt;&amp;]:before:h-2 [ul&gt;&amp;]:before:bg-red-600 [ul&gt;&amp;]:before:rounded-full marker:inline group-[.isActiveSource]:text-xl\">a seguran\u00e7a da vacina;<\/li>\n<li class=\"[ul&gt;&amp;]:indent-5 mb-3 break-words [ul&gt;&amp;]:relative [ul&gt;&amp;]:before:absolute [ul&gt;&amp;]:before:left-1 [ul&gt;&amp;]:before:top-2 [ul&gt;&amp;]:before:w-2 [ul&gt;&amp;]:before:h-2 [ul&gt;&amp;]:before:bg-red-600 [ul&gt;&amp;]:before:rounded-full marker:inline group-[.isActiveSource]:text-xl\">as rea\u00e7\u00f5es \u00e0 aplica\u00e7\u00e3o;<\/li>\n<li class=\"[ul&gt;&amp;]:indent-5 mb-3 break-words [ul&gt;&amp;]:relative [ul&gt;&amp;]:before:absolute [ul&gt;&amp;]:before:left-1 [ul&gt;&amp;]:before:top-2 [ul&gt;&amp;]:before:w-2 [ul&gt;&amp;]:before:h-2 [ul&gt;&amp;]:before:bg-red-600 [ul&gt;&amp;]:before:rounded-full marker:inline group-[.isActiveSource]:text-xl\">a capacidade de estimular uma resposta imunol\u00f3gica no organismo.<\/li>\n<\/ul>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Esses resultados v\u00e3o <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">orientar as pr\u00f3ximas etapas<\/strong>, que ser\u00e3o necess\u00e1rias para saber se a vacina de fato protege contra a doen\u00e7a.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\"><strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">Cr\u00e9dito: Reprodu\u00e7\u00e3o\/CT Vacinas<\/strong><\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">Para o pesquisador <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">Ricardo Gazzinelli<\/strong>, caso a seguran\u00e7a e efic\u00e1cia da vacina sejam comprovadas, isso poder\u00e1 ser visto como uma ferramenta de estrat\u00e9gia de controle do mosquito.<\/p>\n<blockquote class=\"relative -z-10 my-10 rounded bg-neutral-100 px-6 py-11 lg:bg-neutral-50 lg:px-20 lg:py-10\" data-quote=\"true\">\n<p>Essa vacina pode ter um papel extremamente importante para eliminar a mal\u00e1ria do nosso territ\u00f3rio e, com isso, tamb\u00e9m contribuir com a elimina\u00e7\u00e3o da mal\u00e1ria na Am\u00e9rica Latina.<\/p>\n<p>Ricardo Gazzinelli, coordenador do CTVacinas<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\"><strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">Mal\u00e1ria no Brasil<\/strong><\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">A mal\u00e1ria \u00e9 causada por parasitas do g\u00eanero <strong class=\"group-[.isActiveSource]:text-xl group-[.isActiveSource]:font-bold\">Plasmodium<\/strong>, transmitidos pela picada de f\u00eameas infectadas do mosquito Anopheles. Os sintomas mais comuns s\u00e3o febre, calafrios e dor de cabe\u00e7a.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">De acordo com a Organiza\u00e7\u00e3o Mundial da Sa\u00fade (OMS), em 2024 foram estimados 282 milh\u00f5es de casos de mal\u00e1ria e 610 mil \u00f3bitos em 80 pa\u00edses.<\/p>\n<p class=\"my-5 break-words group-[.isActiveSource]:text-xl\" style=\"text-align: justify;\">No Brasil, a regi\u00e3o amaz\u00f4nica concentra mais de 99% dos casos aut\u00f3ctones de mal\u00e1ria. Integram essa \u00e1rea os estados do Acre, Amazonas, Amap\u00e1, Maranh\u00e3o, Mato Grosso, Par\u00e1, Rond\u00f4nia, Roraima e Tocantins.<\/p>\n<p style=\"text-align: justify;\"><strong>Fonte: <a href=\"https:\/\/www.cnnbrasil.com.br\/saude\/anvisa-autoriza-testes-em-humanos-de-vacina-brasileira-contra-malaria\/#goog_rewarded\" rel=\"nofollow noopener\" target=\"_blank\">CNN.<\/a><\/strong><\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"Trata-se da Vivaxin, imunizante que pretende combater a infec\u00e7\u00e3o causada pelo parasita plasmodium vivax, um dos principais causadores&hellip;\n","protected":false},"author":2,"featured_media":567600,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[86],"tags":[5671,91773,91774,116,11486,3536,62933,32,1461,33,5950,117,896,91775,31507,6833,3064,88803,91776],"class_list":["post-567599","post","type-post","status-publish","format-standard","has-post-thumbnail","category-saude","tag-anvisa","tag-cristalia","tag-fase-1","tag-health","tag-malaria","tag-pesquisa-cientifica","tag-plasmodium-vivax","tag-portugal","tag-prevencao","tag-pt","tag-resposta-imunologica","tag-saude","tag-saude-publica","tag-seguranca-vacinal","tag-testes-clinicos","tag-ufmg","tag-usp","tag-vacina-brasileira","tag-vivaxin"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@pt\/117513254831758503","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/posts\/567599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/comments?post=567599"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/posts\/567599\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/media\/567600"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/media?parent=567599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/categories?post=567599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/pt\/wp-json\/wp\/v2\/tags?post=567599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}